A positive prostate biopsy means cancer cells were found in one or more of the tissue samples taken from your prostate. This is not an emergency. Most prostate cancers are slow-growing, and the overall 5-year survival rate across all stages is 98%. You have time to understand your results, get additional testing if needed, and make a treatment decision that fits your situation.
What Your Biopsy Report Actually Tells You
Your pathology report will contain several pieces of information, but the most important is the Gleason score and its corresponding Grade Group. These describe how aggressive the cancer cells look under a microscope. The Gleason score is the sum of two numbers, each ranging from 1 to 5, that grade the two most common cell patterns found in your samples. A lower total means the cells still look relatively normal; a higher total means they look more abnormal and are likely to grow faster.
The Grade Group system simplifies this into five categories:
- Grade Group 1 (Gleason 6 or less): Low-risk. The most common finding. These cancers grow slowly and may never need treatment.
- Grade Group 2 (Gleason 3+4=7): Favorable intermediate-risk. Mostly lower-grade cells with some higher-grade mixed in.
- Grade Group 3 (Gleason 4+3=7): Unfavorable intermediate-risk. The same total score as Group 2, but the more aggressive pattern dominates.
- Grade Group 4 (Gleason 8): High-risk.
- Grade Group 5 (Gleason 9 or 10): Highest risk. These cancers are most likely to grow and spread.
Your report will also note how many of the biopsy cores contained cancer and what percentage of each core was affected. If cancer was found in most of your cores, that signals a larger tumor. Men with more than 50% positive cores are at meaningfully higher risk of the cancer having spread beyond the prostate.
How Staging Works After a Positive Biopsy
The Grade Group tells you how aggressive the cancer cells are. Staging tells you where the cancer is and whether it has spread. Your clinical stage is based on the biopsy results, any imaging you’ve had, and the digital rectal exam your doctor performed.
At the earliest stage (T1), the tumor can’t be felt during an exam or seen on imaging. It was only detected because your PSA was elevated and the biopsy came back positive. At T2, the tumor can be felt or seen on ultrasound but is still contained within the prostate. At T3, the cancer has grown through the outer wall of the prostate and may have reached the seminal vesicles nearby.
For cancers that are localized (confined to the prostate) or regional (spread only to nearby areas), the 5-year survival rate is greater than 99%. Even when prostate cancer has spread to distant parts of the body, the 5-year survival rate is 38%, and treatments continue to improve. These numbers come from men diagnosed between 2015 and 2021.
Additional Tests You Might Need
Depending on your Grade Group and how much cancer was found, your doctor may order further testing before discussing treatment. An MRI of the prostate can show whether the tumor extends beyond the gland. A newer type of scan called a PSMA PET scan is particularly useful for detecting whether cancer has spread to lymph nodes or bones. It works by targeting a protein found on the surface of prostate cancer cells.
PSMA PET scans are most valuable for men with unfavorable intermediate or high-risk disease. Research published in the Journal of Nuclear Medicine found that among men with unfavorable intermediate-risk cancer, those with more than 75% positive biopsy cores had roughly four times the odds of the scan revealing metastatic disease compared to men with fewer positive cores. For men with the lowest-risk profiles, the chance of finding spread was only about 3%, so the scan often isn’t necessary.
Genomic tests are another tool that can sharpen your picture. One widely used test analyzes the activity of 22 genes in your tumor tissue and produces a score from 0 to 1. Men with scores above 0.6 had a 15% rate of the cancer eventually spreading, compared to 6% for men with scores below 0.45. Less than 1% of men in the low-score group died from prostate cancer, versus 10% in the high-score group. These tests can help you and your doctor decide whether aggressive treatment is necessary or whether a more conservative approach is safe.
Your Treatment Options
Treatment depends on the cancer’s grade, stage, your age, and your overall health. The main paths are active surveillance, surgery, and radiation therapy.
Active Surveillance
For Grade Group 1 cancers and some Grade Group 2 cancers, active surveillance is a standard approach. This means monitoring the cancer closely with regular PSA tests, repeat biopsies, and imaging rather than treating it immediately. Many low-grade prostate cancers never progress to the point where they need treatment. Active surveillance avoids the side effects of surgery or radiation while keeping treatment available if the cancer shows signs of becoming more aggressive.
Surgery
Radical prostatectomy removes the entire prostate gland. For men with localized disease, 10-year survival exceeds 99% for lower-risk cancers and is about 96% for higher-risk cancers. The main side effects are urinary leakage and changes in sexual function. About 14% of men with low-risk cancer reported urinary leakage 10 years after surgery, and roughly a quarter of men with higher-risk cancer reported the same. Sexual function problems were more common in the first five years after surgery compared to other treatments, though by the 10-year mark the differences between surgery and radiation were no longer significant for men with low-risk disease.
Radiation Therapy
External beam radiation delivers targeted energy to the prostate from outside the body. Ten-year survival rates are comparable to surgery across risk categories. Urinary leakage rates are lower: about 4% for men with low-risk cancer and 11% for those with higher-risk disease at 10 years. For men with high-risk cancer, radiation is typically combined with hormone therapy that temporarily lowers testosterone to slow cancer growth. Genomic testing can help determine which men genuinely benefit from that addition.
You Have Time to Decide
One of the most important things to understand after a positive biopsy is that you are not in a rush. Your body needs several weeks to heal from the biopsy itself, and that recovery window is a natural period to research your options. The Prostate Cancer Foundation specifically advises against rushing into treatment, noting that it’s far better to take some time and make a decision you’re confident in than to act hastily and regret it later.
Use this window to get a second opinion on your pathology, ask about genomic testing if your cancer is intermediate-risk, and understand the side effect profile of each treatment option. Many men find it helpful to consult both a urologist (who performs surgery) and a radiation oncologist to hear both perspectives before choosing. The treatment that’s right for you depends not only on the cancer’s characteristics but on what side effects you’re most willing to accept and how they fit with your daily life.